Display options
Cite
Nath SV, Prince HM, Choong PF, et al. Durable remissions are rare following high dose therapy with autologous stem cell transplantation for adults with "paediatric" bone and soft tissue sarcomas. Int Semin Surg Oncol. 2005;2(1):12doi: 10.1186/1477-7800-2-12.
Nath, S. V., Prince, H. M., Choong, P. F., & Toner, G. C. (2005). Durable remissions are rare following high dose therapy with autologous stem cell transplantation for adults with "paediatric" bone and soft tissue sarcomas. International seminars in surgical oncology : ISSO, 2(1), 12. https://doi.org/10.1186/1477-7800-2-12
Nath, Shriram V, et al. "Durable remissions are rare following high dose therapy with autologous stem cell transplantation for adults with "paediatric" bone and soft tissue sarcomas." International seminars in surgical oncology : ISSO vol. 2,1 (2005): 12. doi: https://doi.org/10.1186/1477-7800-2-12
Nath SV, Prince HM, Choong PF, Toner GC. Durable remissions are rare following high dose therapy with autologous stem cell transplantation for adults with "paediatric" bone and soft tissue sarcomas. Int Semin Surg Oncol. 2005 May 31;2(1):12. doi: 10.1186/1477-7800-2-12. PMID: 15927067; PMCID: PMC1164428.
Copy Download .nbib Format: NLM
Share it on

Int Semin Surg Oncol. 2005 May 31;2(1):12. doi: 10.1186/1477-7800-2-12.

Durable remissions are rare following high dose therapy with autologous stem cell transplantation for adults with "paediatric" bone and soft tissue sarcomas.

International seminars in surgical oncology : ISSO

Shriram V Nath, H Miles Prince, Peter Fm Choong, Guy C Toner

Affiliations

  1. Haematology Service, Peter MacCallum Cancer Centre, St, Andrew's Place, East Melbourne, Australia. [email protected].

PMID: 15927067 PMCID: PMC1164428 DOI: 10.1186/1477-7800-2-12

Abstract

BACKGROUND: The role of high dose therapy (HDT) with autologous stem cell transplantation (AuSCT) for the treatment of bone and soft tissue sarcomas remains investigational. There are few reports examining this strategy focusing on the adult population. METHODS: We retrospectively reviewed our experience of adult patients undergoing HDT and AuSCT for 'paediatric' sarcomas. RESULTS: A total of 17 patients (14 male, 3 female) with median age at transplant of 24 years (range 20 - 41) were identified. The diagnosis was Ewings sarcoma/PNET (10), osteosarcoma (5) and rhabdomyosarcoma (2). Status prior to HDT, following conventional-dose chemotherapy +/- surgery +/- radiotherapy, was complete remission (CR) (6), partial remission (PR) (6), stable disease (1) and progressive disease (4). There was no transplant-related mortality. Two patients remain disease free beyond four years and both received HDT as part of their primary therapy (CR1 and PR1) however, the median progression free survival and overall survival following AuSCT for the entire cohort was only 7 months (range: 2-92 months) and 13 months (range: 2 - 92 months), respectively. CONCLUSION: HDT and AuSCT infrequently achieves prolonged remissions in adult patients and should only be considered in patients who are in a PR or CR following conventional-dose therapy. Further studies are required to define the role of HDT with AuSCT for adult patients with sarcoma.

References

  1. Eur J Cancer. 1997 Mar;33(3):357-61 - PubMed
  2. Intern Med J. 2004 Jul;34(7):431-4 - PubMed
  3. Ann Oncol. 2000 Nov;11(11):1451-62 - PubMed
  4. Med Pediatr Oncol. 2000 May;34(5):328-37 - PubMed
  5. Arch Surg. 2003 Mar;138(3):281-5 - PubMed
  6. J Clin Oncol. 2000 Nov 1;18(21):3643-50 - PubMed
  7. Bone Marrow Transplant. 1998 Dec;22 Suppl 5:S37-40 - PubMed
  8. Curr Opin Oncol. 2004 Mar;16(2):120-5 - PubMed
  9. J Clin Oncol. 1998 May;16(5):1697-706 - PubMed
  10. Ann Oncol. 2003 Aug;14(8):1167-8 - PubMed
  11. J Clin Oncol. 2001 Jun 1;19(11):2812-20 - PubMed
  12. J Clin Oncol. 1997 Jul;15(7):2611-21 - PubMed
  13. J Clin Oncol. 1993 Oct;11(10):1911-8 - PubMed
  14. Bone Marrow Transplant. 2004 Jul;34(1):37-41 - PubMed
  15. J Clin Oncol. 1999 Jan;17(1):150-7 - PubMed
  16. N Engl J Med. 2003 Feb 20;348(8):694-701 - PubMed
  17. Semin Oncol. 1999 Feb;26(1):119-33 - PubMed
  18. Eur J Cancer. 2001 Jul;37(11):1338-44 - PubMed
  19. Bone Marrow Transplant. 1992 Nov;10(5):405-8 - PubMed
  20. J Clin Oncol. 1993 Jul;11(7):1276-85 - PubMed
  21. Sarcoma. 2003;7(1):1-7 - PubMed
  22. Eur J Cancer. 2003 Jan;39(1):64-9 - PubMed
  23. Bone Marrow Transplant. 2001 May;27(9):933-7 - PubMed
  24. J Clin Oncol. 1993 Aug;11(8):1482-8 - PubMed
  25. J Clin Oncol. 2001 Feb 1;19(3):870-80 - PubMed
  26. Sarcoma. 2003;7(2):43-55 - PubMed
  27. Crit Rev Oncol Hematol. 2002 Feb;41(2):157-67 - PubMed
  28. J Clin Oncol. 1995 Jul;13(7):1537-45 - PubMed
  29. J Clin Oncol. 1993 Jul;11(7):1269-75 - PubMed
  30. Cancer. 1997 Oct 1;80(7):1221-7 - PubMed
  31. J Clin Oncol. 2003 Sep 15;21(18):3423-30 - PubMed
  32. J Clin Oncol. 2002 Apr 15;20(8):2150-6 - PubMed

Publication Types